Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
